Status:
NOT_YET_RECRUITING
Curatively Intended Thoracic Reirradiation
Lead Sponsor:
University of Aarhus
Conditions:
Radiotherapy Side Effect
Radiation Toxicity
Eligibility:
All Genders
Brief Summary
The number of long-term lung cancer (LC) survivors increases, however many patients are diagnosed with recurrent or new thoracic cancers. High-dose reirradiation (reRT) is promising but associated wit...
Detailed Description
1. BACKGROUND: The number of long-term survivors is increasing for thoracic cancers, however, a significant proportion of lung cancer (LC) patients treated with curatively intended radiotherapy (R...
Eligibility Criteria
Inclusion
- Radiotherapy of thoracic lesion(s) (loco-regional lung cancer recurrence, new primary lung cancer, or solitary oligo metastasis) with the aim of long-term local control.
- Reirradiation type 1 or type 2, i.e. previous radiotherapy to the thorax as per ESTRO-EORTC consensus definition of reirradiation \[Andratschke 2022\]. For the sake of this study, multiple treatments to the lungs will be classified as type 2 reirradiation.
- Verification of malignancy based on biopsy. If no biopsy is available, the decision of reirradiation should be agreed upon in a multidisciplinary conference.
- Available digital dose plan(s) from former radiotherapy course(s) (DICOM files) - note that multiple re-treatments are allowed.
- Adequate lung function to tolerate treatment, at the discretion of the treating physician.
- Ability to complete a radiotherapy course with the aim of local control.
- ECOG Performance status 0-2.
- Estimated life expectancy ≥ 6 months
- Age ≥18 years
- Signed informed consent
Exclusion
- Uncontrolled other malignancy.
- The primary and the reirradiation treatment may not be quasi-simultaneous (i.e. the two treatments should be planned independently)
- Pregnancy
- Radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions. Treatment schedule according to local protocols and treating physician preference.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2035
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06950073
Start Date
May 1 2025
End Date
May 1 2035
Last Update
April 29 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.